



2025

SEERS 4Q IR BOOK

WE Make
Medicine Smarter

seers



Disclaimer

Forward-Looking Statements Disclaimer

The accuracy of the forward-looking statements included in this presentation has not been independently verified, and reflect the Company's current views, expectations, and assumptions regarding future events and performance.

Such statements include, but are not limited to, statements relating to the Company's business outlook, strategy, plans, objectives, anticipated financial performance, and market opportunities.

Forward-looking statements may be identified by words such as "expect," "forecast," "plan," "anticipate," "estimate," "intend," "believe," "may," "will," "could," and similar expressions.

Forward-looking statements are based on information available to the Company and management's assumptions as of the date of this presentation and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or outcomes to differ materially from those expressed or implied by such statements.

Factors that could cause actual results to differ materially include, but are not limited to, changes in economic, market, regulatory, and competitive conditions; technological developments; operational execution; and other risks and uncertainties inherent in the Company's business and industry.

The Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contents

Chapter_1
Company Overview

Chapter_2
Core Capabilities

Chapter_3
Business Progress

“

Chapter 1

Company Overview”

01

Chapter 1

About SEERS

02


Chapter 1_ Company Overview

Overview

1. About SEERS

We Make Medicine Smarter+

Empowering the continuum of care



Wearable Medical Devices
Innovative wearable medical devices delivering enhanced user experience and convenience for patients and healthcare professionals

Digital Healthcare Service
Diagnostic and monitoring services powered by wearable medical devices and medical AI

Subscription based BM
Reimbursement-based subscription model improving hospital ROI

Medical AI
Clinically validated AI technologies for diagnosis, prediction, and monitoring enabling efficient clinical care

1. About SEERS_Overview

seers , a pioneer in the digital healthcare market for over 16 years



Company Overview

Founder & CEO	Young-shin Lee
Date of Establishment	August 11, 2009
Listing Date	June 19, 2024
Issued Capital	6.3billion KRW
Number of Employees	144 (as January 2026)
Business Area	Diagnostic support and patient monitoring powered by wearable medical devices and AI
Key Products	mobiCARE™ thynC™
Location	<p>Headquarters: 291-13, Dongbu-daero, Jinwi-myeon, Pyeongtaek-si, Gyeonggi-do</p> <p>R&D Center : 5F, Tower B, 246, Hwangsa-eul-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea</p> <p>Jeju Branch: #308, 40, Cheomdan-ro 8-gil, Jeju-si, Jeju-do</p>

Team



Young shin Lee
Founder & CEO



Hee seok Song
CTO



Kyu seok Bang
COO



Young tae Jang
CFO



Dae yeop Kang
CSO



Seong jong Kim
CBO



Gyung chul Kim
Core R&D Center



Jung hoon Chae
Adhesive Material R&D Center

Shareholders Structure



“ Chapter 2
**Core
Capabilities** ”

01

Chapter 2_ Core Capabilities
mobiCARE™



02

Chapter 2_ Core Capabilities
thynC™

03

Chapter 2_ Core Capabilities
Business Model

Disease Screening & Diagnostic Services via Wearable Medical Devices and AI **mobiCARE™**



● Addressing unmet demand for ECG testing through enhanced patient convenience and subscription-based analysis services

Category	Before (existing method)	After (mobiCARE™)
Upfront Cost	High	Low
Test Environment	Multiple wired cables attached Portable device (500g)	A wearable patch suitable for everyday use
User Convenience	Uncomfortable attachment and restricted activity	Lightweight patch enabling free movement
Monitoring Duration	Within 24 hours	Up to 9 days
Data Processing	Manual review and analysis	Automatic upload with AI-based advanced interpretation

● What is mobiCARE™?

- Wearable ECG analysis solution optimized for arrhythmia detection
- Components: wearable ECG device + cradle (data uploader) + software



Reliability: Proven technology

- No.1 market share provider
- Extensive clinical studies and up to 9 days of continuous monitoring



Convenience: Flexible operation

- Various product and wear options (disposable and reusable)
- User-centric management services, including courier-based return services




Cost-effectiveness: Low barrier to adoption

- **In-house manufacturing facility**
: Cost reduction and quality control
- Stable supply and management system

A new paradigm in wearable AI-based ECG diagnostics

Wearable ECG analysis service optimized for arrhythmia detection



● Outpatient ECG analysis service

AI-based outpatient ECG automated analysis system

- Continuous out-of-hospital monitoring following clinic-based prescription
- Up to 9 days of monitoring with automatic upload, AI analysis, and report generation
- Specialist-reviewed reports through partnerships with arrhythmia-specialized hospitals
- Increased reimbursed revenue by adding arrhythmia testing to existing outpatient examination items

● Arrhythmia screening service (health check-up centers)

One-stop health check-up system


*Deployment of an automated system enabling same-day mobiCARE™ testing and AI-based arrhythmia screening at health check-up centers

- AI-powered arrhythmia screening
- Automatic integration of examinee information and results with ERP/HIS and other systems
- Integrated management of the examinee screening workflow using thynC™
- Real-time abnormality response and strengthened connectivity between clinicians and examinees

thynC™ patient monitoring services powered by wearable medical devices and AI



Before



After



- Secured broad demand across inpatient wards by delivering enhanced convenience for patients and clinicians, along with proven clinical utility


Category	Before (existing method)	After (thynC™)
Monitoring Method	Manual monitoring using fixed in-room equipment	Real-time AI-powered automated monitoring
Data Collection	Individual operation of devices around the patient	Integrated data collection via IoT-connected devices
Alert Method	Manual confirmation and delayed alerts upon abnormal events	Automatic detection of abnormal signs with immediate alerts to clinicians
Spatial Constraints	Equipment clutter around the bed, restricting patient movement	Wireless data collection enabling free patient movement
Operational Efficiency	Manual data recording and review by clinicians	Dashboard-based integrated management, improving workflow efficiency
Patient Experience	Continuous monitoring while confined to the bed	More flexible and comfortable inpatient environment

- An inpatient monitoring platform that delivers real-time patient vital signs from wearable devices to clinicians and detects abnormalities through AI-based analysis

Biosignal Analysis AI	Real-time biosignal analysis and event prediction, abnormality detection, and alerts
Wearable Medical Device	Biosignal monitoring biosensors (ECG, heart rate, respiration, temperature, SpO ₂ , blood pressure)
Network	Fixed/portable wireless network gateways
On-premise server	AI-enabled platform operation server (EMR integration)
Application Software	Remote monitoring and ward management software for nurses and healthcare professionals

Smart Ward Infrastructure Powered by Real-Time AI

Real-Time Inpatient Monitoring System with Wearable Biosensors



3. Business Model

thynC™: Korea's largest AI wearable-based 24/7 monitoring platform and the first in Korea with EMR integration /
mobiCARE™: No.1 domestic market share

mobiCARE™



Outpatient ECG analysis service

Reimbursement-based subscription service

Premium Model
(AI analysis report with specialist review)

E6545 **KRW 60,663**
ECG monitoring – 24-hour Holter recording

E6556 **KRW 161,678**
ECG monitoring – over 48 hours and up to 7 days

E6557 **KRW 220,892**
ECG monitoring – over 7 days and up to 14 days



Arrhythmia screening service (Health check-up centers)

Non-reimbursed subscription service

Same-Day Screening Model
(AI analysis report)

Premium Model
(AI analysis report with specialist review)

- Same-day screening model: AI-based screening using on-site measurements during the visit
- Post-screening pathway: Symptomatic individuals are referred to a 3-day premium diagnostic test
- Premium model packages: 1-day / 2-day / 3-day / 7-day monitoring options

thynC™



Hospital (inpatient) patients

Reimbursement-based subscription service

Subscription to AI analysis and monitoring reports

System sales services by bed capacity

- System sales models by bed capacity (10 / 20 / 30 / 40 beds)
- Hospital-wide deployment model for smart ward operations
- + Maintenance services and sales of wearable biosensor consumables

EX871 Remote heart rate monitoring (per day) **KRW 45,701**

E6544 Bedside ECG monitoring (per day) **KRW 19,412**

E7230 Transcutaneous oxygen saturation measurement (per day) **KRW 10,292.5**

E6548 24-hour ambulatory blood pressure monitoring (per day) **KRW 18,434.5**

E6556 **KRW 161,678**
E6557 **KRW 220,892**
ECG monitoring

“

Chapter 3

Business Progress

”

01

Chapter 3_ Business Progress
Technical Capabilities

02

Chapter 3_ Business Progress
Competitive Advantage of the Solution

03

Chapter 3_ Business Progress
Advancement of the Diagnostic Platform

04

Chapter 3_ Business Progress
Global Market Expansion

05

Chapter 3_ Business Progress
Summary Financials

Integrated capabilities to establish a digital healthcare service platform by leveraging medical AI and wearable biosensors

Proprietary Medical AI Technologies

- Equipped with AI technology for biosensor-based signal analysis
- Applicable to a wide range of conditions, including emergency arrhythmias, atrial fibrillation, heart failure, sepsis, and cardiac arrest

Wireless Wearable Biosensor Technology

- Implementation of diverse wireless biosensors: ECG, thermometer, blood pressure monitor, and SpO2.
- Secured core technologies in embedded systems, wireless network solutions, and secure wireless transmission protocols

Remote Patient Monitoring and Telemedicine Service Platform Technology

Comprehensive full-cycle telemedicine technologies including IoMT network solutions, real-time AI analysis algorithms, cloud/on-premise servers, app/web software, WebRTC video communication, and secure messaging

Manufacturing Infrastructure for Wearable Medical Devices

- Operating wearable medical device manufacturing facilities certified by GMP and ISO 13485
- Established in-house cleanroom infrastructure for the specialized production of bio-materials

Skin-adhesive biomaterial technology

- Secured expertise in formulation and processing technologies for skin-adhesive materials, including silicones and hydrogels
- Proprietary Transdermal Drug Delivery System (TDDS) technology



3. mobiCARE™ Diagnostic Platform Enhancement

Enhancing the mobiCARE™ diagnostic platform through expanded AI-based ECG analysis services and extension into adjacent therapeutic areas

+ Advancing AI-Based Innovative Medical Devices

Wearable AI-based arrhythmia diagnostic service

Class II Holter monitor medical device

Reimbursement codes secured: E6545 / E6556 / E6557



Atrial fibrillation prediction



Heart failure prediction



Myocardial infarction prediction



+ Expansion of ECG Analysis Service Areas



Multi-channel ECG devices
Expanded ECG analysis service coverage



Simplified ECG devices
B2C arrhythmia prevention services



MCT (Mobile Cardiac Telemetry)
Remote arrhythmia monitoring services



Arrhythmia diagnostic services for companion animals

+ Expansion of ECG testing for adjacent therapeutic areas



Obstetrics & Gynecology
Ovulation detection



Psychiatry
Autonomic nervous system assessment



Pulmonology
Sleep disorder assessment




Nephrology
Hypocalcemia assessment



Rehabilitation Medicine
Exercise stress testing

3. thynC™ Diagnostic Platform Enhancement

Advancement of the thynC platform through predictive programs utilizing real-time biometric data and upselling of AI-powered wearable devices



+ Improving outcomes through AI-Powered Innovative Solutions | Value-added Services | Expansion of integration with third-party monitoring devices

- Malignant arrhythmia prediction
- Cardiac arrest prediction
- Sepsis prediction
- Pneumonia prediction

+

- Early Warning Score
- Fall detection
- Patient location tracking
- Early fever detection

+

- IV infusion monitoring
 - Continuous glucose monitoring (CGM)
 - Post-void residual urine monitoring
 - Ring-type blood pressure monitoring
 - Cardiac output monitoring
- Building the thynC™ ecosystem in collaboration with diverse digital healthcare companies, including EMG sensors, spirometers, medical AI, voice EMR, and EMR interface providers

4. Global Market Expansion

Growth into a global digital healthcare company through the commercialization and export of diagnostic and monitoring services

mobiCARE™
thynC™

	Mongolia	Hong Kong	Kazakhstan	Vietnam	UAE	USA
Local Partner	Medicont	BTL	Open Healthcare	MITA Medtech	OneHealth	CBS
Regulatory Approval	Completed	Completed	Completed	Completed	Completed	In Progress
Clinical Validation Sites	National CV Center	Queen Mary Hospital	Almati Heart Center	BachMai Hospital	SSMC	St. Lukes Hospital
Progress Status	mobiCARE™ Analysis Center	Remote ECG analysis service	mobiCARE™ Analysis Center	mobiCARE™ Analysis Center	mobiCARE™ Analysis Center	mobiCARE™ Analysis Center

* Countries with regulatory approval process planned or in-progress: Europe, Thailand, Pakistan, Australia, Canada, Saudi Arabia, Singapore, and Malaysia

** Other countries with regulatory approval: Paraguay

5. Summary Financials

● Summary Balance Sheet

Unit: KRW million

Category	2022	2023	2024	2025.3Q
Current assets	11,890	5,871	16,442	27,478
Non-current assets	9,403	11,276	11,642	13,176
Total assets	21,293	17,147	28,084	40,594
Current liabilities	2,746	6,729	3,880	6,885
Non-current liabilities	539	2,309	2,805	3,408
Total liabilities	3,285	0,038	6,685	10,294
Issued capital	1,369	5,477	6,276	6,333
Capital surplus	42,310	38,189	60,030	60,793
Elements of other stockholder's equity	317	413	287	723
Retained earnings (deficit)	(25,988)	(35,970)	(45,194)	(37,549)
Total equity	18,008	8,109	21,399	30,300

● Summary Income Statement

Unit: KRW million

Category	2022	2023	2024	2025.3Q
Revenue	1,153	1,885	8,100	27,759
Cost of sales	1,704	2,709	4,664	8,284
Selling general administrative expenses	7,439	8,979	12,117	11,721
Operating income	(7,990)	(9,803)	(8,681)	7,754
Finance income	75	92	284	184
Finance costs	95	213	394	174
Other gains	22	15	13	3
Other losses	-	8	-	6
Other income (expense) from subsidiaries, jointly controlled entities and associates	-	-	-	(116)
Profit (loss) before tax	(7,988)	(9,917)	(8,778)	7,645
Tax expense	-	-	93	-
Profit (loss)	(7,988)	(9,917)	(8,871)	7,645

“

Thank you.

”

seers
2025 4Q IR Book